Advanced Filters
noise
Found 2,152 clinical trials
U UCLH Research

A Study of NX-1607 in Adults With Advanced Malignancies

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.

18 years of age All Phase 1
H Hong Shue, MD

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral ONM-501 as monotherapy and in combination with a PD-1 checkpoint inhibitor in patients with advanced solid tumors and …

18 years of age All Phase 1

Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors

This is a first-in-human, single-arm, open-label, dose escalation clinical study to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics, immunogenicity and preliminary efficacy of UCMYM802 (Circular mRNA encoding Anti-Mesothelin CAR-T) injection in patients with Mesothelin-positive advanced malignant solid tumors.

18 - 70 years of age All Phase 1

A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue

The purpose of this study is to find out whether lattice radiation therapy (LRT) is an effective radiation therapy technique when compared to standard stereotactic body radiation therapy (SBRT). The study will also study how the different radiation therapy techniques (LRT and SBRT) affect how many immune cells are able …

18 years of age All Phase N/A
C Carrie Friedman

A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With Select Solid Tumors

The goal of this clinical trial is to evaluate the safety of TOS-358 in adults with select solid tumors who meet study enrollment criteria. The main questions it aims to answer are: what is the maximum tolerated dose and recommended dose for phase 2? how safe and tolerable is TOS-358 …

18 years of age All Phase 1
F Francesco Violante, MD

Night-shift Work and Breast Cancer

Scientific evidence established about the effects of night work on health both in the short term (insomnia, excessive sleepiness, difficulty concentrating or lack of energy) and in the long term (moderately high risk of developing cardiovascular disease, type 2 diabetes, depression, cancer). In light of the scientific evidence, the IARC …

20 - 70 years of age Female Phase N/A
L Laetitia SOMEIL-TAVAKKOLI

SENOVIE France - Therapeutic Mobility and Breast Cancer

Background In France, there were 61,214 new cases of breast cancer in France in 2023 with an estimated prevalence in 2017 of 913,089 people. It is thus the most common cancer in women, with an incidence that has been increasing since 1990, due both to changes in screening but more …

18 years of age Female Phase N/A
M Maria Agudelo, MD

PRECAMA: Molecular Subtypes of Premenopausal Breast Cancer in Latin American Women

Breast cancer has become a major public health problem in Latin America, as it is the most common form of cancer among women. Women are more likely to develop breast cancer at younger age, and to be diagnosed at an advanced stage compared to western women. Over the past twenty …

20 - 45 years of age Female Phase N/A
C Christian Laflamme, PhD

Long-term Safety of Nipple Sparing Mastectomy in Women With GPV in Breast Cancer

Patients with a germline pathogenic variant (GPV) in high-penetrance breast cancer susceptibility genes who are considering risk reducing mastectomy (RRM) often strongly desire to keep their nipple areola complex but inquire as to whether it is safe to do so. Relative to traditional or skin sparing mastectomy (SSM) techniques, nipple …

18 - 90 years of age Female Phase N/A

Long-Term Follow-up Study of Early Stage Breast Cancer Patients Included in GEICAM Studies

This is a multicenter, cohorts study to collect information from patients diagnosed with early-stage invasive breast cancer who have been previously included in a neoadjuvant or adjuvant clinical trial of the GEICAM group. Patients will be included in this study from the moment of completion of the follow-up of the …

18 years of age Female Phase N/A

Simplify language using AI